Treatment of orbital myositis with adalimumab (Humira).
Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.
Adams
Alexa B
AB
Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.
Kazim
Michael
M
Lehman
Thomas J A
TJ
D000068879:Adalimumab; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016727:Orbital Pseudotumor / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab